| 证券代码 | ONTXW.O |
| 证券名称 | Onconova Therapeutics Inc Wt |
| 证券类型 | 美国权证 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | - |
| 发行方式 | - |
| 首发上市日 | 2016-08-03 |
| 首发价格(元) | - |
| 首发数量(股) | 0 |
| 首发募资额(元) | - |
| 首发主承销商 | - |
| 货币单位 | - |
| 公司名称 | Onconova Therapeutics, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 375 Pheasant Run, Newtown, Pennsylvania, USA |
| 成立日期 | 1998-12 |
| 董事会主席 | - |
| 公司属地 | United States 美国 |
| 公司网址 | www.onconova.com |
| 电话 | +1 (267) 759-3680 |
| 传真 | +1 (267) 759-3681 |
| 公司简介 | Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS). Rigosertib, Onconova’s lead candidate, is a proprietary Phase 3 small molecule agent, which the Company believes blocks cellular signaling by targeting RAS effector pathways. Using a proprietary chemistry platform, Onconova has created a pipeline of targeted agents designed to work against specific cellular pathways that are important in cancer cells. Onconova has three product candidates in the clinical stage and several pre-clinical programs. Advanced clinical trials with the Company’s lead compound, rigosertib, are aimed at what the Company believes are unmet medical needs of patients with MDS. |